{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:04:36Z","timestamp":1792037076532,"version":"4.4.0"},"reference-count":128,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T00:00:00Z","timestamp":1623974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Despite not being utilized as considerably as other antidepressants in the therapy of depression, the monoamine oxidase inhibitors (MAOIs) proceed to hold a place in neurodegeneration and to have a somewhat broad spectrum in respect of the treatment of neurological and psychiatric conditions. Preclinical and clinical studies on MAOIs have been developing in recent times, especially on account of rousing discoveries manifesting that these drugs possess neuroprotective activities. The altered brain levels of monoamine neurotransmitters due to monoamine oxidase (MAO) are directly associated with various neuropsychiatric conditions like Alzheimer\u2019s disease (AD). Activated MAO induces the amyloid-beta (A\u03b2) deposition via abnormal cleavage of the amyloid precursor protein (APP). Additionally, activated MAO contributes to the generation of neurofibrillary tangles and cognitive impairment due to neuronal loss. No matter the attention of researchers on the participation of MAOIs in neuroprotection has been on monoamine oxidase-B (MAO-B) inhibitors, there is a developing frame of proof indicating that monoamine oxidase-A (MAO-A) inhibitors may also play a role in neuroprotection. The therapeutic potential of MAOIs alongside the complete understanding of the enzyme\u2019s physiology may lead to the future advancement of these drugs.<\/jats:p>","DOI":"10.3390\/molecules26123724","type":"journal-article","created":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T11:19:20Z","timestamp":1624015160000},"page":"3724","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":305,"title":["Role of Monoamine Oxidase Activity in Alzheimer\u2019s Disease: An Insight into the Therapeutic Potential of Inhibitors"],"prefix":"10.3390","volume":"26","author":[{"given":"Tapan","family":"Behl","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Chitkara College of Pharmacy, Chitkara University, Rajpura 140401, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dapinder","family":"Kaur","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Chitkara College of Pharmacy, Chitkara University, Rajpura 140401, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aayush","family":"Sehgal","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Chitkara College of Pharmacy, Chitkara University, Rajpura 140401, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukhbir","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Chitkara College of Pharmacy, Chitkara University, Rajpura 140401, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelam","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Chitkara College of Pharmacy, Chitkara University, Rajpura 140401, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gokhan","family":"Zengin","sequence":"additional","affiliation":[{"name":"Department of Biology, Faculty of Science, Selcuk University Campus, 42130 Konya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5670-3456","authenticated-orcid":false,"given":"Felicia Liana","family":"Andronie-Cioara","sequence":"additional","affiliation":[{"name":"Department of Psycho-Neuroscience and Recovery, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirela Marioara","family":"Toma","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania"},{"name":"Doctoral School of Biomedical Sciences, University of Oradea, 410073 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3236-1292","authenticated-orcid":false,"given":"Simona","family":"Bungau","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania"},{"name":"Doctoral School of Biomedical Sciences, University of Oradea, 410073 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian Gheorghe","family":"Bumbu","sequence":"additional","affiliation":[{"name":"Department of Surgical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Alzheimer\u2019s Association (2015). Alzheimer\u2019s disease facts and figures. Alzheimers Dement., 11, 332\u2013384.","DOI":"10.1016\/j.jalz.2015.02.003"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_3","unstructured":"Prince, M., Wimo, A., Guerchet, M., Ali, G.-C., Wu, Y.-T., and Prina, M. (2013). World Alzheimer Report, Alzheimer\u2019s Disease International."},{"key":"ref_4","first-page":"1005","article-title":"Inflammation in Alzheimer disease: Driving force, bystander or beneficial response?","volume":"12","year":"2006","journal-title":"Nat. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.arr.2014.07.004","article-title":"When astrocytes become harmful: Functional and inflammatory responses that contribute to Alzheimer\u2019s disease","volume":"18","author":"Arias","year":"2014","journal-title":"Ageing Res. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.tins.2009.08.002","article-title":"Molecular dissection of reactive astrogliosis and glial scar formation","volume":"32","author":"Sofroniew","year":"2009","journal-title":"Trends Neurosci."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Meraz Rios, M.A., Toral-Rios, D., Franco-Bocanegra, D., Villeda-Hern\u00e1ndez, J., and Campos-Pe\u00f1a, V. (2013). Inflammatory process in Alzheimer\u2019s Disease. Front. Integr. Neurosci., 7.","DOI":"10.3389\/fnint.2013.00059"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1046\/j.1471-4159.1999.0732310.x","article-title":"Monoamine oxidase and mitochondrial respiration","volume":"73","author":"Cohen","year":"1999","journal-title":"J. Neurochem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.3892\/mmr.2014.2040","article-title":"Monoamine oxidase inhibitors: Promising therapeutic agents for Alzheimer\u2019s disease","volume":"9","author":"Cai","year":"2014","journal-title":"Mol. Med. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0197-4580(00)00100-7","article-title":"Monoamine oxidase-B inhibitors in the treatment of Alzheimers disease","volume":"21","author":"Thomas","year":"2000","journal-title":"Neurobiol. Aging"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1002\/mds.870080504","article-title":"The relevance of glial monoamine oxidase-B and polyamines to the action of selegiline in parkinson\u2019s disease","volume":"8","author":"Youdim","year":"1993","journal-title":"Mov. Disord."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0304-3940(02)00307-5","article-title":"Increased monoamine oxidase messenger RNA expression levels in frontal cortex of Alzheimer\u2019s disease patients","volume":"326","author":"Emilsson","year":"2002","journal-title":"Neurosci. Lett."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.neuint.2010.10.013","article-title":"Activated MAO-B in the brain of Alzheimer patients, demonstrated by (1C)-L-deprenyl using whole hemisphere autoradiography","volume":"58","author":"Pavlova","year":"2011","journal-title":"Neurochem. Int."},{"key":"ref_14","unstructured":"Rahman, K. (2007). Studies on free radicals, antioxidants, and co-factors. Clin. Interv. Aging, 2."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2967\/jnumed.110.087031","article-title":"Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: A multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG","volume":"53","author":"Carter","year":"2012","journal-title":"J. Nucl. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJM199704243361704","article-title":"A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer\u2019s disease","volume":"336","author":"Sano","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Magni, G., and Meibach, R. (1999). Lazabemide for the long-term treatment of Alzheimer\u2019s disease. Eur. Neuropsychopharmacol., 9.","DOI":"10.1016\/S0924-977X(99)80017-0"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrn1883","article-title":"The therapeutic potential of monoamine oxidase inhibitors","volume":"7","author":"Youdim","year":"2006","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ejmech.2018.01.003","article-title":"Privileged scaffolds as MAO inhibitors: Retrospect and prospects","volume":"145","author":"Tripathi","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.2174\/156802612805219978","article-title":"Monoamine oxidases: The biochemistry of the proteins as targets in medicinal chemistry and drug discovery","volume":"12","author":"Ramsay","year":"2012","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/jlcr.3779","article-title":"Synthesis and characterization of novel radiofluorinated probes for positron emission tomography imaging of monoamine oxidase B","volume":"62","author":"Yoshimoto","year":"2019","journal-title":"J. Label. Compd. Radiopharm."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.phrs.2010.09.001","article-title":"On the formation and nature of the imidazoline I2 binding site on human monoamine oxidase-B","volume":"62","author":"McDonald","year":"2010","journal-title":"Pharmacol. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2174\/13816128113190990406","article-title":"Hydrogen peroxide produced by mitochondrial monoamine oxidase catalysis: Biological implications","volume":"20","author":"Edmondson","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.abb.2009.07.019","article-title":"Oxidation of amines by flavoproteins","volume":"493","author":"Fitzpatrick","year":"2010","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2174\/1573408052952711","article-title":"Monoamine oxidase inhibition in the light of new structural data","volume":"1","author":"Fierro","year":"2005","journal-title":"Curr. Enzym. Inhib."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1021\/jm070677y","article-title":"Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: Safinamide and coumarin analogs","volume":"50","author":"Binda","year":"2007","journal-title":"J. Med. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"42660","DOI":"10.1039\/C6RA00302H","article-title":"Recent developments on the structure-activity relationship studies of MAO inhibitors and their role in different neurological disorders","volume":"6","author":"Kumar","year":"2016","journal-title":"RSC Adv."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5739","DOI":"10.1073\/pnas.0710626105","article-title":"Structure of human monoamine oxidase A at 2.2-\u00c5 resolution: The control of opening the entry for substrates\/inhibitors","volume":"105","author":"Son","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"12684","DOI":"10.1073\/pnas.0505975102","article-title":"Three-Dimensional structure of human monoamine oxidase A (MAO A): Relation to the structures of rat MAO A and human MAO B","volume":"102","author":"Li","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1039\/C8MD00446C","article-title":"Discovery of monoamine oxidase inhibitors by medicinal chemistry approaches","volume":"10","author":"Hong","year":"2019","journal-title":"MedChemComm"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1345\/aph.17150","article-title":"Donepezil use in Alzheimer disease","volume":"32","author":"Barner","year":"1998","journal-title":"Ann. Pharmacother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00702-003-0828-6","article-title":"Early and persistent alterations in prefrontal cortex MAO A and B in Alzheimer\u2019s disease","volume":"110","author":"Kennedy","year":"2003","journal-title":"J. Neural Transm."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0006-8993(98)01211-6","article-title":"Accumulation of 3, 4-dihydroxyphenylglycolaldehyde, the neurotoxic monoamine oxidase A metabolite of norepinephrine, in locus ceruleus cell bodies in Alzheimer\u2019s disease: Mechanism of neuron death","volume":"816","author":"Burke","year":"1999","journal-title":"Brain Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000107290","article-title":"Calbindin D-28k and monoamine oxidase A immunoreactive neurons in the nucleus basalis of Meynert in senile dementia of the Alzheimer type and Parkinson\u2019s disease","volume":"4","author":"Savaskan","year":"1993","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1023\/A:1020764504462","article-title":"Pargyline conjugate-induced long-term activation of monoamine oxidase as an immunological model for depression","volume":"24","author":"Danilova","year":"1999","journal-title":"Neurochem. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0021-5198(19)39985-8","article-title":"Deamination of norepinephrine, dopamine, and serotonin by type A monoamine oxidase in discrete regions of the rat brain and inhibition by RS-8359","volume":"55","author":"Kumagae","year":"1991","journal-title":"Jpn. J. Pharmacol."},{"key":"ref_37","first-page":"9","article-title":"The importance of norepinephrine in depression","volume":"7","author":"Moret","year":"2011","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.brainresbull.2008.12.004","article-title":"Regional changes in the cholinergic system in mice lacking monoamine oxidase A","volume":"78","author":"Grailhe","year":"2009","journal-title":"Brain Res. Bull."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1517\/14656566.2011.534983","article-title":"Pharmacotherapy of social anxiety disorder","volume":"12","author":"Schneier","year":"2011","journal-title":"Expert Opin. Pharm."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s12031-011-9583-6","article-title":"Neuroprotective effect of cyclooxygenase inhibitors in ICV-STZ induced sporadic Alzheimer\u2019s disease in rats","volume":"46","author":"Dhull","year":"2012","journal-title":"J. Mol. Neurosci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.pnpbp.2009.07.004","article-title":"Platelet serotonin concentration and monoamine oxidase type B activity in female patients in early, middle and late phase of Alzheimer\u2019s disease","volume":"33","author":"Presecki","year":"2009","journal-title":"Prog. Neuro Psychopharmacol. Biol. Psychiatry"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3233\/JAD-2010-100150","article-title":"Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid protein precursor: Involvement of MAPK and PKC activation","volume":"21","author":"Amit","year":"2010","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1021\/cn300095t","article-title":"5-HT4 receptors constitutively promote the non-amyloidogenic pathway of APP cleavage and interact with ADAM10","volume":"4","author":"Cochet","year":"2013","journal-title":"ACS Chem. Neurosci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1021\/acscentsci.6b00309","article-title":"Close correlation of monoamine oxidase activity with progress of Alzheimer\u2019s disease in mice, observed by in vivo two-photon imaging","volume":"2","author":"Kim","year":"2016","journal-title":"ACS Cent. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Streit, W.J. (2010). Microglial activation and neuroinflammation in Alzheimer\u2019s disease: A critical examination of recent history. Front. Aging Neurosci., 2.","DOI":"10.3389\/fnagi.2010.00022"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0306-4522(94)90311-5","article-title":"Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography","volume":"62","author":"Saura","year":"1994","journal-title":"Neuroscience"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0306-4522(91)90098-9","article-title":"Monoamine oxidase B in brains from patients with Alzheimer\u2019s disease: A biochemical and autoradiographical study","volume":"45","author":"Jossan","year":"1991","journal-title":"Neuroscience"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"6212","DOI":"10.1016\/j.bmc.2005.06.043","article-title":"Human recombinant monoamine oxidase B as reliable and efficient enzyme source for inhibitor screening","volume":"13","author":"Novaroli","year":"2005","journal-title":"Bioorg. Med. Chem."},{"key":"ref_49","first-page":"1","article-title":"Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with \u03b3-secretase and regulates neuronal amyloid \u03b2-peptide levels","volume":"9","author":"Inoue","year":"2017","journal-title":"Alzheimers Res. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Quartey, M.O., Nyarko, J.N., Pennington, P.R., Heistad, R.M., Klassen, P.C., Baker, G.B., and Mousseau, D.D. (2018). Alzheimer disease and selected risk factors disrupt a co-regulation of monoamine oxidase-A\/B in the hippocampus, but not in the cortex. Front. Neurosci., 12.","DOI":"10.3389\/fnins.2018.00419"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Park, J.-H., Ju, Y.H., Choi, J.W., Song, H.J., Jang, B.K., Woo, J., Chun, H., Kim, H.J., Shin, S.J., and Yarishkin, O. (2019). Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer\u2019s disease. Sci. Adv., 5.","DOI":"10.1126\/sciadv.aav0316"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1124\/jpet.117.241653","article-title":"Sembragiline: A novel, selective monoamine oxidase type B inhibitor for the treatment of Alzheimer\u2019s disease","volume":"362","author":"Borroni","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12888-016-0785-x","article-title":"Discovering biomarkers for antidepressant response: Protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort","volume":"16","author":"Lam","year":"2016","journal-title":"BMC Psychiatry"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1124\/pr.59.2.1","article-title":"Neurotoxicity and metabolism of the catecholamine-derived 3, 4-dihydroxyphenylacetaldehyde and 3, 4-dihydroxyphenylglycolaldehyde: The role of aldehyde dehydrogenase","volume":"59","author":"Marchitti","year":"2007","journal-title":"Pharmacol. Rev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cotox.2018.12.002","article-title":"Biogenic aldehyde-mediated mechanisms of toxicity in neurodegenerative disease","volume":"13","author":"Cagle","year":"2019","journal-title":"Curr. Opin. Toxicol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s00702-019-02082-0","article-title":"Selegiline: A molecule with innovative potential","volume":"127","author":"Youdim","year":"2020","journal-title":"J. Neural Transm."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0161-813X(03)00106-2","article-title":"Monoamine oxidase-B inhibition in Alzheimer\u2019s disease","volume":"25","author":"Riederer","year":"2004","journal-title":"Neurotoxicology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1007\/s11064-010-0293-1","article-title":"Site-Activated chelators derived from anti-Parkinson drug rasagiline as a potential safer and more effective approach to the treatment of Alzheimer\u2019s disease","volume":"35","author":"Zheng","year":"2010","journal-title":"Neurochem. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00702-011-0597-6","article-title":"Iron-Chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer\u2019s disease: A tribute to Moussa Youdim","volume":"118","author":"Weinreb","year":"2011","journal-title":"J. Neural Transm."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ejmech.2014.04.078","article-title":"Donepezil+ propargylamine+ 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer\u2019s disease","volume":"80","author":"Wang","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"ref_61","unstructured":"Wood, P.L. (2006). Neurodegeneration and aldehyde load: From concept to therapeutics. J. Psychiatry Neurosci. JPN, 31."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2174\/1874467211003020066","article-title":"Potential role of acrolein in neurodegeneration and in Alzheimer\u2019s disease","volume":"3","author":"Arseneault","year":"2010","journal-title":"Curr. Mol. Pharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.freeradbiomed.2016.12.046","article-title":"Linking lipid peroxidation and neuropsychiatric disorders: Focus on 4-hydroxy-2-nonenal","volume":"111","author":"Romano","year":"2017","journal-title":"Free Radic. Biol. Med."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Taso, O.V., Philippou, A., Moustogiannis, A., Zevolis, E., and Koutsilieris, M. (2019). Lipid peroxidation products and their role in neurodegenerative diseases. Ann. Res. Hosp., 3.","DOI":"10.21037\/arh.2018.12.02"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1080\/10408440591002183","article-title":"Aldehyde sources, metabolism, molecular toxicity mechanisms, and possible effects on human health","volume":"35","author":"Siraki","year":"2005","journal-title":"Crit. Rev. Toxicol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Abdel-Daim, M.M., Abo-EL-Sooud, K., Aleya, L., Bung\u0103u, S.G., Najda, A., and Saluja, R. (2018). Alleviation of drugs and chemicals toxicity: Biomedical value of antioxidants. Oxid. Med. Cell. Longev., 2018.","DOI":"10.1155\/2018\/6276438"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2174\/1573400511309020008","article-title":"Thiol metabolism in schizophrenia: Current status","volume":"9","author":"Wood","year":"2013","journal-title":"Curr. Psychiatry Rev."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1447-0594.2009.00571.x","article-title":"Lipids\u2019 peroxidation markers in Alzheimer\u2019s disease and vascular dementia","volume":"10","author":"Kowalczuk","year":"2010","journal-title":"Geriatr. Gerontol. Int."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2174\/156720510791383822","article-title":"The serum protein and lipid oxidation marker levels in Alzheimer\u2019s disease and effects of cholinesterase inhibitors and antipsychotic drugs therapy","volume":"7","author":"Sinem","year":"2010","journal-title":"Curr. Alzheimer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/toxsci\/kfu233","article-title":"Molecular mechanisms of acrolein toxicity: Relevance to human disease","volume":"143","author":"Moghe","year":"2015","journal-title":"Toxicol. Sci."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s12640-020-00278-x","article-title":"An intensified acrolein exposure can affect memory and cognition in rat","volume":"39","author":"Khoramjouy","year":"2021","journal-title":"Neurotox. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.toxlet.2012.12.023","article-title":"Acrolein induces Alzheimer\u2019s disease-like pathologies in vitro and in vivo","volume":"217","author":"Huang","year":"2013","journal-title":"Toxicol. Lett."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s12017-012-8191-0","article-title":"Methylglyoxal induces tau hyperphosphorylation via promoting AGEs formation","volume":"14","author":"Li","year":"2012","journal-title":"Neuromol. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/j.freeradbiomed.2010.02.016","article-title":"Increased levels of 4-hydroxynonenal and acrolein in the brain in preclinical Alzheimer disease","volume":"48","author":"Bradley","year":"2010","journal-title":"Free Radic. Biol. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cbi.2019.03.003","article-title":"Attenuation of the effects of oxidative stress by the MAO-inhibiting antidepressant and carbonyl scavenger phenelzine","volume":"304","author":"Baker","year":"2019","journal-title":"Chem. Biol. Interact."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"35151","DOI":"10.1007\/s11356-019-06660-3","article-title":"Protective effects of hesperidin and diosmin against acrylamide-induced liver, kidney, and brain oxidative damage in rats","volume":"26","author":"Elhelaly","year":"2019","journal-title":"Environ. Sci. Pollut. Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/jcbfm.2012.211","article-title":"Phenelzine mitochondrial functional preservation and neuroprotection after traumatic brain injury related to scavenging of the lipid peroxidation-derived aldehyde 4-hydroxy-2-nonenal","volume":"33","author":"Singh","year":"2013","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_78","first-page":"2132","article-title":"The 4-hydroxynonenal mediated oxidative damage of blood proteins and lipids involves secondary lipid peroxidation reactions","volume":"16","author":"Mustafa","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/10177833.2010.11790656","article-title":"Phenelzine: An old drug that may hold clues to the development of new neuroprotective agents","volume":"20","author":"MacKenzie","year":"2010","journal-title":"Klin. Psikofarmakol. B\u00fcl. Bull. Clin. Psychopharmacol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s00702-013-0978-0","article-title":"Comparison of phenelzine and geometric isomers of its active metabolite, \u03b2-phenylethylidenehydrazine, on rat brain levels of amino acids, biogenic amine neurotransmitters and methylamine","volume":"120","author":"Matveychuk","year":"2013","journal-title":"J. Neural Transm."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/ddr.1202","article-title":"\u03b2-phenylethylidenehydrazine, a novel inhibitor of GABA transaminase","volume":"54","author":"Paslawski","year":"2001","journal-title":"Drug Dev. Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0165-0173(03)00170-X","article-title":"Anti-epileptic drugs as possible neuroprotectants in cerebral ischemia","volume":"42","author":"Leker","year":"2003","journal-title":"Brain Res. Rev."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1523\/JNEUROSCI.21-03-00798.2001","article-title":"Adaptive plasticity in tachykinin and tachykinin receptor expression after focal cerebral ischemia is differentially linked to gabaergic and glutamatergic cerebrocortical circuits and cerebrovenular endothelium","volume":"21","author":"Stumm","year":"2001","journal-title":"J. Neurosci."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.schres.2014.12.026","article-title":"The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia","volume":"167","author":"Cohen","year":"2015","journal-title":"Schizophr. Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1001\/jamaneurol.2013.234","article-title":"An imbalance between excitatory and inhibitory neurotransmitters in amyotrophic lateral sclerosis revealed by use of 3-T proton magnetic resonance spectroscopy","volume":"70","author":"Foerster","year":"2013","journal-title":"JAMA Neurol."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Kim, Y.S., and Yoon, B.-E. (2017). Altered GABAergic signaling in brain disease at various stages of life. Exp. Neurobiol., 26.","DOI":"10.5607\/en.2017.26.3.122"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-016-0609-4","article-title":"Altered excitatory-inhibitory balance within somatosensory cortex is associated with enhanced plasticity and pain sensitivity in a mouse model of multiple sclerosis","volume":"13","author":"Potter","year":"2016","journal-title":"J. Neuroinflamm."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/mp.2010.120","article-title":"The GABAergic deficit hypothesis of major depressive disorder","volume":"16","author":"Luscher","year":"2011","journal-title":"Mol. Psychiatry"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1016\/j.bmc.2005.04.072","article-title":"Design and biological evaluation of phenyl-substituted analogs of \u03b2-phenylethylidenehydrazine","volume":"13","author":"Sowa","year":"2005","journal-title":"Bioorg. Med. Chem."},{"key":"ref_90","unstructured":"Sowa, B., Knaus, E., Todd, K., Davood, A., and Baker, G. (2003). Biochemical activity of 4-fluorophenylethyl-idenehydrazine and its potential as a neuroprotectant in cerebral ischemia. J. Neurochem., 85."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Shanahan, P., O\u2019Sullivan, J., Tipton, K.F., Kinsella, G.K., Ryan, B.J., and Henehan, G.T. (2019). Theobromine and related methylxanthines as inhibitors of primary amine oxidase. J. Food Biochem., 43.","DOI":"10.1111\/jfbc.12697"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1161\/01.RES.0000134630.68877.2F","article-title":"Origins of serum semicarbazide-sensitive amine oxidase","volume":"95","author":"Stolen","year":"2004","journal-title":"Circ. Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1111\/j.1471-4159.2006.04181.x","article-title":"Potential implications of endogenous aldehydes in \u03b2-amyloid misfolding, oligomerization and fibrillogenesis","volume":"99","author":"Chen","year":"2006","journal-title":"J. Neurochem."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3109\/10408363.2015.1050714","article-title":"Vascular adhesion protein-1: Role in human pathology and application as a biomarker","volume":"52","author":"Pannecoeck","year":"2015","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s00702-007-0701-0","article-title":"Semicarbazide-Sensitive amine oxidase (SSAO) and its possible contribution to vascular damage in Alzheimer\u2019s disease","volume":"114","author":"Unzeta","year":"2007","journal-title":"J. Neural Transm."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1002\/jnr.23092","article-title":"Immunohistochemical study of semicarbazide-sensitive amine oxidase\/vascular adhesion protein-1 in the hippocampal vasculature: Pathological synergy of Alzheimer\u2019s disease and diabetes mellitus","volume":"90","author":"Valente","year":"2012","journal-title":"J. Neurosci. Res."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"O\u2019Rourke, A., Wang, E., Salter-Cid, L., Huang, L., Miller, A., Podar, E., Gao, H., Jones, D., and Linnik, M. (2007). Benefit of inhibiting SSAO in relapsing experimental autoimmune encephalomyelitis. J. Neural Transm., 114.","DOI":"10.1007\/s00702-007-0699-3"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1111\/bph.13573","article-title":"The inhibitor of semicarbazide-sensitive amine oxidase, PXS-4728A, ameliorates key features of chronic obstructive pulmonary disease in a mouse model","volume":"173","author":"Jarnicki","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"ref_99","first-page":"1","article-title":"Analgesic and anti-inflammatory effects of the novel semicarbazide-sensitive amine-oxidase inhibitor SzV-1287 in chronic arthritis models of the mouse","volume":"7","author":"Menghis","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/jcbfm.2010.167","article-title":"Vascular adhesion protein-1 inhibition provides antiinflammatory protection after an intracerebral hemorrhagic stroke in mice","volume":"31","author":"Ma","year":"2011","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1080\/13813455.2017.1415939","article-title":"Phenelzine reduces the oxidative damage induced by peroxynitrite in plasma lipids and proteins","volume":"124","author":"Mustafa","year":"2018","journal-title":"Arch. Physiol. Biochem."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1152\/physrev.00044.2005","article-title":"The NOX family of ROS-generating NADPH oxidases: Physiology and pathophysiology","volume":"87","author":"Bedard","year":"2007","journal-title":"Physiol. Rev."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jacc.2017.05.043","article-title":"Oxidative stress and cardiovascular risk: Obesity, diabetes, smoking, and pollution: Part 3 of a 3-part series","volume":"70","author":"Niemann","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.brainres.2008.03.023","article-title":"Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatments","volume":"1211","author":"Balu","year":"2008","journal-title":"Brain Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.neuroscience.2005.12.058","article-title":"Antidepressants reverse corticosterone-mediated decrease in brain-derived neurotrophic factor expression: Differential regulation of specific exons by antidepressants and corticosterone","volume":"139","author":"Dwivedi","year":"2006","journal-title":"Neuroscience"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1023\/A:1026119708124","article-title":"Antioxidant effect of phenelzine on MPP+-induced cell viability loss in differentiated PC12 cells","volume":"28","author":"Lee","year":"2003","journal-title":"Neurochem. Res."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Joseph, T.P., Nataraj Jagadeesan, L.Y.S., Lin, S.L., Sahu, S., and Schachner, M. (2020). Adhesion molecule L1 agonist mimetics protect against the pesticide paraquat-induced locomotor deficits and biochemical alterations in zebrafish. Front. Neurosci., 14.","DOI":"10.3389\/fnins.2020.00458"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.pbb.2018.05.013","article-title":"Phenelzine, a cell adhesion molecule L1 mimetic small organic compound, promotes functional recovery and axonal regrowth in spinal cord-injured zebrafish","volume":"171","author":"Li","year":"2018","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1007\/s00213-016-4342-6","article-title":"Effects of anti-depressant treatments on FADD and p-FADD protein in rat brain cortex: Enhanced anti-apoptotic p-FADD\/FADD ratio after chronic desipramine and fluoxetine administration","volume":"233","year":"2016","journal-title":"Psychopharmacology"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1046\/j.1471-4159.2001.00285.x","article-title":"N-Acetylaspartate, a marker of both cellular dysfunction and neuronal loss: Its relevance to studies of acute brain injury","volume":"77","author":"Demougeot","year":"2001","journal-title":"J. Neurochem."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2174\/138945012799499794","article-title":"Ladostigil: A novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer\u2019s disease treatment","volume":"13","author":"Weinreb","year":"2012","journal-title":"Curr. Drug Targets"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Birks, J., and Flicker, L. (2003). Selegiline for Alzheimer\u2019s disease. Cochrane Database Syst. Rev., 1.","DOI":"10.1002\/14651858.CD000442"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JAD-2012-120013","article-title":"From anti-Parkinson\u2019s drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer\u2019s disease","volume":"30","author":"Zheng","year":"2012","journal-title":"J. Alzheimers Dis."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s12640-009-9128-8","article-title":"Limited potentiation of blood pressure in response to oral tyramine by the anti-Parkinson brain selective multifunctional monoamine oxidase-AB inhibitor, M30","volume":"18","author":"Gal","year":"2010","journal-title":"Neurotox. Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/BF02041242","article-title":"The discovery of antidepressants: A winding path","volume":"47","author":"Pletscher","year":"1991","journal-title":"Experientia"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0301-0082(99)00050-7","article-title":"Conventional and new antidepressant drugs in the elderly","volume":"61","author":"Gareri","year":"2000","journal-title":"Prog. Neurobiol."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Makkar, R., Behl, T., Bungau, S., Zengin, G., Mehta, V., Kumar, A., Uddin, M.S., Ashraf, G.M., Abdel-Daim, M.M., and Arora, S. (2020). Nutraceuticals in neurological disorders. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21124424"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"6505","DOI":"10.1007\/s11356-019-07344-8","article-title":"Synergistic antioxidant effects of resveratrol and curcumin against fipronil-triggered oxidative damage in male albino rats","volume":"27","author":"AlBasher","year":"2020","journal-title":"Environ. Sci. Pollut. Res."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Parkinson Study Group (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: The PRESTO study. Arch. Neurol., 62, 241\u2013248.","DOI":"10.1001\/archneur.62.2.241"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ana.410390106","article-title":"Impact of deprenyl and tocopherol treatment on Parkinson\u2019s disease in DATATOP subjects not requiring levodopa","volume":"39","author":"Shoulson","year":"1996","journal-title":"Ann. Neurol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0140-6736(05)71083-7","article-title":"Rasagiline as an adjunct to levodopa in patients with Parkinson\u2019s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): A randomised, double-blind, parallel-group trial","volume":"365","author":"Rascol","year":"2005","journal-title":"Lancet"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/mds.20057","article-title":"A \u201ccure\u201d for Parkinson\u2019s disease: Can neuroprotection be proven with current trial designs?","volume":"19","author":"Clarke","year":"2004","journal-title":"Mov. Disord."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1017\/S1461145799001522","article-title":"Does phenylethylamine act as an endogenous amphetamine in some patients?","volume":"2","author":"Janssen","year":"1999","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/BF02815121","article-title":"L-Deprenyl induces aromatic l-amino acid decarboxylase (AADC) mRNA in the rat substantia nigra and ventral tegmentum","volume":"35","author":"Li","year":"1998","journal-title":"Mol. Chem. Neuropathol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"51S","DOI":"10.1097\/00004714-199508001-00010","article-title":"The therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in Parkinson\u2019s disease","volume":"15","author":"Sieradzan","year":"1995","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0278-5846(03)00053-8","article-title":"A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson\u2019s disease","volume":"27","author":"Weinstock","year":"2003","journal-title":"Prog. Neuro Psychopharmacol. Biol. Psychiatry"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s00213-005-2229-z","article-title":"Effect of chronic treatment with ladostigil (TV-3326) on anxiogenic and depressive-like behaviour and on activity of the hypothalamic-pituitary-adrenal axis in male and female prenatally stressed rats","volume":"181","author":"Poltyrev","year":"2005","journal-title":"Psychopharmacology"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1007\/s00415-004-0481-5","article-title":"Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model","volume":"251","author":"Waibel","year":"2004","journal-title":"J. Neurol."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/12\/3724\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:18:29Z","timestamp":1760163509000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/26\/12\/3724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,18]]},"references-count":128,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["molecules26123724"],"URL":"https:\/\/doi.org\/10.3390\/molecules26123724","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,18]]}}}